The UCI today announced that Katusha rider Eduard Vorganov has been provisionally suspended for an anti-doping rule violation. Vorganov tested positive for the anti-ischemic drug Meldonium in an out-of-competition test on January 14, 2016.
The positive is the second in 12 months for Katusha after Italian Luca Paolini came up positive for cocaine at the Tour de France last year. Under the revised UCI Anti-Doping Rules, the team now faces a possible 15-45 day suspension from competition, depending on the decision of the Disciplinary Commission.
Meldonium, a drug manufactured in Latvia, is new to the WADA prohibited list this year after studies proved that athletes were using the drug to enhance performance. According to an article in Drug Testing and Analysis, researchers found it "demonstrates an increase in endurance performance of athletes, improved rehabilitation after exercise, protection against stress, and enhanced activations of central nervous system (CNS) functions."
ADVERTISEMENT
Should the UCI Disciplinary Commission decided to ban Katusha, the team could be excluded from competing in a number of important early-season events such as the Tour of Qatar, Tour of Oman, Ruta del Sol, and Vuelta Murcia.
The Katusha team said in a statement that it would conduction an investigation into how this "breach of the Team's strict medical and anti-doping internal rules" occurred.
Katusha's riders are prohibited from taking any medicine or supplement unless provided by team doctors, and the team confirmed that Meldonium has neer been used by the team or provided to Vorganov.
You can read more at Cyclingnews.com
via Cyclingnews Latest News http://ift.tt/1mk1yE3
No comments:
Post a Comment